RenovoRx (NASDAQ: RNXT), a biopharmaceutical company using targeted chemotherapy to treat difficult-to-reach tumors, recently presented at the H.C. Wainwright Bioconnect Virtual Conference, a gathering for public and private companies and investors alike. The conference took place January 10-13, 2022, with RenovoRx’s CEO Shaun Bagai presenting on the first day.
RenovoRx’s proprietary platform RenovoTAMP, used to target tricky tumors without affecting non-target areas, was the recipient of the Fierce Innovations Awards – Life Sciences Edition in 2020 in the Drug Delivery Technology category. The company also possesses patents across the US, Europe and Asia.
The H.C. Wainwright Bioconnect Virtual Conference provides public and private companies with the opportunity to network and share information about themselves with potential investors and clients via presentations and 1-on-1 meetings with company management.
A recording of RenovoRx’s presentation at this conference can be viewed here.